Triglycerides and Coronary Heart Disease: A Global Perspective

Keys A. Coronary heart disease in seven countries. Circulation 1970; 41 (Suppl 1): 1–199.

LaRosa JC He J Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340–2346.

Criqui MH Heiss G Cohn R Cowan LD Suchindran CM Bangidwala S Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993; 328: 1220–1225.

Hulley SB Rosenman RH Bawol RD Brand RJ. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease. N Engl J Med 1980; 302: 1383–1389.

Hokanson JE Austin MA. Plasma triglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213–219.

A well executed meta-analysis which demonstrated the impact of triglycerides on coronary heart disease event rates, even after controlling for high-density lipoprotein cholesterol.

Jeppesen J Hein HO Suadicani P Gyntelberg F. Relation of high triglyceride-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease: an 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol 1997; 17: 1114–1120.

Miller M. The epidemiology of triglyceride as a coronary artery disease risk factor. Clin Cardiol 1999; 22(suppl II): II-1–II-6.

Haim M Benderly M Brunner D Behar S Graff E Reicher-Reiss H Goldbourt U. for the BIP Study Group. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease. The Bezafibrate Infarction Prevention (BIP) Registry. Circulation 1999; 100: 475–482.

Goldstein JL Sohrott HG Hazzard WR Bierman EL Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52: 1544–1568.

Stampfer MJ Krauss RM Ma J Blanche PJ Holl LG Sacks FM Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276: 882–888.

Assmann G Schulte H. The importance of triglycerides: results from the Prospective Cardiovascular Munster (PROCAM) Study. Eur J Epidemiol 1992; 8: 99–103.

Manninen V Tenkanen L Koskinen P Huttunen JK Manttari M Heinonen OP Frick H. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentration on coronary heart disease risk in the Helsinki Heart Study. Circulation 1992; 85: 37–45.

The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000; 102: 21–27. An important secondary prevention study that showed no difference in coronary heart disease event rates in hyperlipidemic (versus control) patients treated with bezafibrate. However, post-hoc analysis revealed that in a subgroup of patients with mixed hyperlipidemia (triglyceride > 200 mg/dl), an approximate 40% reduction in coronary heart disease events were observed.

Uemura K Pisa Z. Trends in cardiovascular mortality in industrialized countries since 1950. World Health Stat Quart 1988; 41: 155–178.

Simons L. Triglyceride levels and the risk of coronary artery disease: a view from Australia. Am J Cardiol 1992; 70 (suppl): 14H–18H.

Connelly PW MacLean DR Horlick L O'Connor B Petrasovits A Little JA Plasma lipids and lipoproteins and the prevalence of risk for coronary heart disease in Canadian adults. Can Med Assoc J 1992; 146: 1977–1987.

Pocock S Shaper A Phillips A. Concentration of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart disease. BMJ 1989; 298: 998–1002.

Cambien F Jacqueson J Richard J Wamet P Ducimetiere P Claude JR. Is the level of serum triglyceride a significant predictor of coronary death in ‘normocholesterolemic’ subjects: the Paris Prospective Study. Am J Epidemiol 1986; 124: 624–632.

Cremer P Nagel D Mann H Labrot B Muller-Berninger R Elster H Seidel D. Ten-year follow-up results from the Goettingen risk, incidence and prevalence study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis 1997; 129: 221–230.

Sigurdsson G Baldursdottir A Sigvaldson H Agnarsson U Thorgeirsson G Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992; 69: 1251–1254.

Haim M Benderly M Brunner D Behar S Graff E Reicher-Reiss H Gouldbourt U. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. Circulation 1999; 100: 475–482.

Menotti A Spagnolo M Scanga M Dima F. Multivariate prediction of coronary deaths in a 10 year follow-up of an Italian occupational cohort. Acta Cardiol 1992; 4: 311–320.

Sakurai Y Kono S Shinchi K Honjo S Todoroki I Wakabayashi K Relation of waist–hip ratio to glucose tolerance, blood pressure, and serum lipids in middle-aged Japanese males. Int J Obesity 1995; 19: 632–637.

Smith WCS Tunstall-Pedoe H Crombie I Tavendale R. Concomitants of excess coronary deaths – major risk factors and lifestyle findings rrom 10 359 men and women in the Scottish Heart Health Study. Scot Med J 1989; 34: 550–555.

Masia R Pena A Marrugat J Sala J Vila J Parvesi M High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. J Epidemiol Co mm Health 1998; 52: 707–715.

Aberg H Lithell H Selinus I Hedstrand H. Serum triglycerides are a risk factor for myocardial infarction but not for angina pectoris: results from a 10-year follow-up of Upsala Primary Preventive Study. Atherosclerosis 1985; 54: 89–97.

US-USSR Steering Committee for Problem Area 1: the Pathogenesis of Atherosclerosis. Collaborative US–USSR study on the prevalence of dyslipoproteinemias and ischemic heart disease in American and Soviet populations. Am J Cardiol 1977; 40: 260–268.

Avins AL Neuhaus JM. Do triglycerides provide meaningful information about heart disease risk? Arch Intern Med 2000; 160: 1937–1944.

Jha P Enas EA Yusuf S. Coronary artery disease in Asian Indians: prevalence and risk factors. Asian Am Pac Islander J Health 1993; 1: 161–175.

Enas EA Yusuf S Mehta JL. Prevalence of coronary artery disease in Asian-Indians. Am J Cardiol 1992; 70: 945–949. A succinct review shedding light on the mechanisms subserving the higher likelihood of coronary heart disease events in Asian-Indians.

Miller M Rhyne J Khatta M Parekh H Zeller K. Prevalence of the APOC3 promoter polymorphisms T-455C and C-482T in Asian Indians. Am J Cardiol 2000 (in press).

Li WW Dammerman MM Smith JD Metzger S Breslow JL Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995; 96: 2601–2605. An elegant study demonstrating the impact of APOC3 promoter polymorphisms on insulin regulation and triglyceride metabolism.

Wenxun F Parker R Parpia B Yinsheng Q Cassano P Crawford M Erythrocyte fatty acids, plasma lipids, and cardiovascular disease in rural China. Am J Clin Nutr 1990; 52: 1027–1036.

Calle EE Thun MJ Petrelli JM Rodriguez C Heath CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341: 1097–1105.

The lipid research clinics populaton studies data book. Vol 1: The prevalence study. Report No. 80–1527. Washington, DC: US Department of Health and Human Services, Public Health Service; 1980.

Johnson CL Rifkind BM Sempos CT Carroll MD Bachorik PS Briefel RR Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys. JAMA 1993; 269: 3002–3008.

Alexander CM Landsman PB Boccuzzi SJ Berger ML. Impaired fasting glucose, lipid levels and prevalence of coronary heart disease. Diabetes 1998; 47(suppl 1): A75.

Ounpau S Anand S Yusuf S. The impending global epidemic of cardiovascular diseases. Eur Heart J 2000; 21: 880–882.

Anand SS Yusuf Vuksan V Devanesen S Montague P Kelemen L The study of health assessment and risk in ethnic groups (SHARE): rationale and design. Can J Cardiol 1998; 14: 1349–1357.

Miller M Byington R Hunninghake D Pitt B Furberg CD. for the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Arch Intern Med 2000; 160: 343–347.

Batalla A Sgadari A Schwandt P Miller M. Underutilization of lipid lowering therapy in patients with coronary disease. Arch Intern Med 2000 (in press).